HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial

Authors:
  • MAManal Abdelmalek
    Manal Abdelmalek
  • JCJaeduk Choi
    Jaeduk Choi
  • YKYoungmin Kim
    Youngmin Kim
  • KSKyounghee Seo
    Kyounghee Seo
  • MHMarcus Hompesch
    Marcus Hompesch
  • SBSeungjae Baek
    Seungjae Baek

Abstract
No abstract available